NetworkNewsBreaks – Silo Pharma Inc. (SILO), Fro
Post# of 137
(Total Views: 162)
Posted On: 05/06/2022 5:32:42 PM
NetworkNewsBreaks – Silo Pharma Inc. (SILO), Frontage Laboratories to Collaborate in Pharmacokinetic Study
Silo Pharma (OTCQB: SILO) recently announced an agreement with Frontage Laboratories, a contract research organization, for an Investigational New Drug (“IND”)-enabling pharmacokinetic study. “Silo merges traditional therapeutics with psychedelic research to relieve patients suffering from PTSD, Alzheimer’s, Parkinson’s, and other rare neurological disorders,” a recent article reads. “Frontage will study Silo’s central nervous system peptide, SPU-16, ’a potential new treatment for multiple sclerosis and other conditions,’ and the company’s joint homing peptide, SPU-21, used for treating arthritogenic processes, which, according to Silo Pharma CEO Eric Weisblum, could, ‘enhance the therapeutic effect of current and future therapeutics while decreasing potential systemic toxicity…. They may be used to treat both central nervous system and autoimmune diseases.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Silo Pharma (OTCQB: SILO) recently announced an agreement with Frontage Laboratories, a contract research organization, for an Investigational New Drug (“IND”)-enabling pharmacokinetic study. “Silo merges traditional therapeutics with psychedelic research to relieve patients suffering from PTSD, Alzheimer’s, Parkinson’s, and other rare neurological disorders,” a recent article reads. “Frontage will study Silo’s central nervous system peptide, SPU-16, ’a potential new treatment for multiple sclerosis and other conditions,’ and the company’s joint homing peptide, SPU-21, used for treating arthritogenic processes, which, according to Silo Pharma CEO Eric Weisblum, could, ‘enhance the therapeutic effect of current and future therapeutics while decreasing potential systemic toxicity…. They may be used to treat both central nervous system and autoimmune diseases.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)SILO Pharma Inc. (SILO) Stock Research Links
Scroll down for more posts ▼